AstraZeneca Suspends COVID-19 Vaccine Trial on Safety Concern

Be the First to Comment Read

AstraZeneca Suspends COVID-19 Vaccine Trial on Safety Concern

UK based pharma major, AstraZeneca Plc (LON:AZN), which is developing COVID-19 vaccine with the University of Oxford stated that it had paused late-stage trial of the COVID-19 vaccine candidate.

The trial was put on hold after a volunteer developed some unexplained illness.

AstraZeneca/Oxford COVID-19 vaccine AZD1222 is under late-stages of clinical trials.

The Company stated it voluntarily paused vaccination for review of safety information by an independent committee.

The interruption of the clinical trial has impacted other vaccine trials of AstraZeneca and ongoing trials by other vaccine developers.

Disclaimer

Speak your Mind

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK